Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, December 24, 2024

GLP-1s tied to a ‘particularly noteworthy’ decrease in likelihood of a dementia diagnosis

Ask your competent? doctor if this would reduce your excess risk of dementia to zero. Maybe you'll want to try this for your dementia risk. 

Is your competent? doctor closely following this because of your extra risk of dementia post stroke?

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%December 2013.`    

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

What they are: 

Drugs like Ozempic, Wegovy, Zepbound and Mounjaro have been around for years, but they’ve recently been making headlines due to a rise in popularity as weight loss agents. They all belong to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), which mimic a hormone (GLP-1) in the body that helps control insulin and blood glucose levels and promotes feelings of satiety.

 I fall into this category:  I now have a BMI of 28 because my doctor failed to get me 100% recovered so I could continue my active life that kept my weight in check. High blood pressure is controlled by drugs.

What are the indications for GLP-1 weight loss?
GLP-1 Medications: Everything You Need to Know
For weight loss, healthcare professionals may prescribe GLP-1 agonists for people with an initial BMI of 30 or higher or people who have a BMI of 27 or higher and at least one weight-related health condition, such as: type 2 diabetes. prediabetes. high blood pressure.


GLP-1s tied to a ‘particularly noteworthy’ decrease in likelihood of a dementia diagnosis

Key takeaways:

  • Patients prescribed GLP-1s had up to a 44% reduced likelihood of a dementia diagnosis.
  • The results show the importance of considering cognitive health in patients with diabetes, a researcher said.

Several glucagon-like peptide-1, or GLP-1, receptor agonists may be associated with reduced risk for a dementia diagnosis in older adults with diabetes, according to a recent study from Epic Research.

The findings add to research on links between diabetes medications and the development of cognitive disorders.Risk for dementia.

Data derived from Epic Research report on “Medications associated with reduced likelihood of dementia compared to other diabetic meds.

“The reduced likelihood of dementia among patients prescribed GLP-1 medications, ranging from 23% to 44%, is significant,” Kristen Bartelt, RN, a research clinician with Epic Research, told Healio.

She added that the consistency of the decreased likelihood of dementia diagnosis across the different medications “was particularly noteworthy.”

Past studies have reported associations between GLP-1 receptor agonists and dementia, with some suggesting a reduced dementia risk after starting the medication and others “indicating variability depending on how these medications cross the blood-brain barrier,” Bartlet and colleagues wrote.

In the current study — which did not undergo peer review — the researchers assessed the likelihood of a dementia diagnosis within 5 years of starting a GLP-1 receptor agonist or another diabetes medication using a cohort of 549,822 patients aged 60 years or older with type 2 diabetes.

The GLP-1 receptor agonists studied included semaglutide (Wegovy/Ozempic, Novo Nordisk), exenatide (Bydureon, AstraZeneca), liraglutide (Saxenda, Novo Nordisk) and dulaglutide (Trulicity, Eli Lilly).

The researchers adjusted for several factors, including BMI and HbA1c at baseline, Social Vulnerability Index, sex, age, race and ethnicity and insulin use history.

Meanwhile, they defined dementia as vascular and nonvascular dementias and Alzheimer’s disease.

Bartelt and colleagues found that patients prescribed semaglutide were 44% less likely to receive a dementia diagnosis vs. those who received a medication that was not a GLP-1 receptor agonist.

Meanwhile, patients prescribed exenatide, liraglutide and dulaglutide had a 32%, 27% and 23% lower likelihood of receiving a dementia diagnosis, respectively.

The data “[underscore] the importance of considering long-term cognitive health when managing a patient’s diabetes,” Bartelt told Healio.

No comments:

Post a Comment